The theme of this year’s annual conference is ‘Revolutionising Clinical Pharmacology: Meeting the Challenge & Leading the Way’.
Our CEO Dr Jorg Taubel will be attending the event in person which will include cutting-edge educational sessions that include a diverse, global representation of Faculty Speakers from clinical, academic, industry, regulatory and consulting perspectives.
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
